AbbVie (NYSE:ABBV) is a global, research-based biopharmaceutical company formed in 2013 following its separation from Abbott Laboratories. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases. AbbVie employs approximately 25,000 people worldwide and markets medicines in more than 170 countries. AbbVie is represented in Germany with headquarters in Wiesbaden and a research and production site in Ludwigshafen. In total, AbbVie Germany has about 2400 employees.
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146 affiliates and a total of more than 47,700 employees. The focus of the family-owned company, founded in 1885, is on researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine. In 2014, Boehringer Ingelheim achieved net sales of about 13.3 billion euros. R&D expenditure corresponds to 19.9% of its net sales. Boehringer Ingelheim’s successes in research and development continuously strengthen its portfolio of medications and offer patients true therapeutic benefit. The company’s research focuses on four areas of strength: immunology and respiratory diseases, cardiometabolic diseases, diseases of the central nervous system, and oncology. With its research functions “Scientific Platforms” and “Research Beyond Borders”, Boehringer Ingelheim is prepared to leverage synergies by investigating scientific concepts with potential in more than one disease area and by exploring emerging science and technology, both within and outside the current research therapeutic focus of Boehringer Ingelheim.
At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it.
Johnson & Johnson Innovation is working to accelerate scientific innovation at all stages of development worldwide in order to deliver cutting-edge solutions for patients’ unmet needs. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one-stop access to the broad resources of the Johnson & Johnson family of companies across the pharmaceutical, medical devices and consumer healthcare segments.
The biopharmaceutical division of Merck, headquartered in Darmstadt, Germany, offers leading brands in 150 countries to help patients with cancer, multiple sclerosis, infertility, and endocrine and metabolic disorders, as well as cardiovascular diseases. In the United States and Canada, EMD Serono operates as a separately incorporated subsidiary of Merck. Merck discovers, develops, manufactures and markets prescription medicines of both chemical and biological origin for specialist indications. We have an enduring commitment to deliver novel therapies in our core focus areas of neurology, oncology, immuno-oncology and immunology.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and is a frontrunner in diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapeutics. In 2014, the Roche Group employed 88,500 people worldwide, invested 8.9 billion Swiss francs in R&D, and posted sales of 47.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.